Page 2 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |Sanofi Announcements | Sanofi: Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

no ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s notable to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.” In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.

United statesFrance generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherSally bainJohn reedFara berkowitzGlobal head of researchNational cancer instituteAmerican society of clinical oncologyData safety monitoring committeeAmerican cancer societyMemorial sloan kettering cancer centerClinical oncology

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Share this article PARIS, May 19, 2021 /PRNewswire/ Phase 1 data from the AMEERA-1 study evaluating amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. In a pooled analysis, amcenestrant in combination with palbociclib showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). These early clinical data show that the combination of amcenestrant with palbociclib achieved encouraging antitumor activity, said Sarat Chandarlapaty, M.D., Ph.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center. The analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It s notable to see this kind of activity in patients with ER+ me

United statesFrance generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherJohn reedSarat chandarlapatyFara berkowitzSally bainGlobal head of researchAmerican society of clinical oncologyData safety monitoring committeeMemorial sloan kettering cancer centerClinical oncologyMedical oncologist

Sanofi: Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Sanofi: Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalEva schaefer jansenSuzanne grecoArnaud delepineFelix lauscherSally bainJohn reedFara berkowitzGlobal head of researchNational cancer instituteAmerican society of clinical oncologyData safety monitoring committeeMemorial sloan kettering cancer centerAmerican cancer societyClinical oncology

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles reports Q1 financial results

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned - London, UK 11 May 2021 - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights. Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end, said Dr Iraj Ali, Chief Executive Officer of Achilles. We continue to enroll and dose patients and have

United statesUnited kingdomCity ofMelissa gardinerCollins tim stamperSukaina virjiMarkwin veldersJulie oneillMiraj aliMary jane elliottAnnabel clayBen atwell natalieCentre phasei iiaData safety monitoring committeeAmerican association of cancer researchResearch development

Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial

Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Republic ofHo chi minh cityH chíinhQuynhn nguyenNational healthData safety monitoring committeeElsevier ltdResearch councilDuc hospitalMerck sharpMedical research councilகுடியரசு ஆஃப்ஹோ சி மிந் நகரம்தேசிய ஆரோக்கியம்தகவல்கள் பாதுகாப்பு கண்காணிப்பு குழுஆராய்ச்சி சபை